PMID- 12825458
OWN - NLM
STAT- MEDLINE
DCOM- 20030721
LR  - 20041117
IS  - 1367-6733 (Print)
IS  - 1367-6733 (Linking)
VI  - 4
IP  - 5
DP  - 2001 Sep
TI  - Mechanisms for modulating TNF alpha in immune and inflammatory disease.
PG  - 635-50
AB  - The development of tumor necrosis factor-alpha (TNF alpha) inhibitors has been 
      one of the most active areas of drug development over the last ten years for the 
      treatment of inflammatory diseases. Following the definition of TNF alpha as a 
      key mediator of inflammatory disease and the success demonstrated by various 
      anti-TNF alpha strategies in the treatment of rheumatoid arthritis and 
      inflammatory bowel disease, many investigators have sought to refine mechanisms 
      by which to modulate TNF alpha in vivo. Many advances are presently being made in 
      the understanding of how TNF alpha production is regulated, and with this 
      knowledge comes the identification of new targets and pathways for therapeutic 
      intervention. Here, we review the development of the currently available 
      therapeutics and the progressive steps that are being made to improve clinical 
      efficacy of anti-TNF alpha strategies.
FAU - Baugh, J A
AU  - Baugh JA
AD  - Picower Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, 
      USA.
FAU - Bucala, R
AU  - Bucala R
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Curr Opin Drug Discov Devel
JT  - Current opinion in drug discovery & development
JID - 100887519
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adjuvants, Immunologic/*pharmacology
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Humans
MH  - Immune System Diseases/*drug therapy
MH  - Inflammation/*drug therapy
MH  - Receptors, Tumor Necrosis Factor/antagonists & inhibitors
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/biosynthesis/genetics
RF  - 145
EDAT- 2003/06/27 05:00
MHDA- 2003/07/23 05:00
CRDT- 2003/06/27 05:00
PHST- 2003/06/27 05:00 [pubmed]
PHST- 2003/07/23 05:00 [medline]
PHST- 2003/06/27 05:00 [entrez]
PST - ppublish
SO  - Curr Opin Drug Discov Devel. 2001 Sep;4(5):635-50.